Physician profile

Gary K Steinberg

Neurological Surgery · Palo Alto, CA

NPI 1013074277

$277,873.65

in general payments reported to CMS, 2019-2025

8 companies · $8,823 in 2025

The $8,823 reported for 2025 was more than what 85% of Neurological Surgery providers received nationally (typical 2025 total: $604).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$26,875.00
Royalty Or License$7,500.00
Travel and Lodging$809.19
Food and Beverage$513.36

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Surgical Theater. INC. $143,625.00 2020-2025
Carl Zeiss Meditec, INC. $52,125.00 2019-2020
Carl Zeiss Meditec USA, INC. $37,500.00 2021-2022
Medtronic USA, INC. $22,129.21 2019
Medtronic, INC. $21,171.89 2021
Medical Device Business Services, INC. $1,292.18 2025
Depuy Synthes Sales INC. $30.37 2025

1 company reported research payments only; those appear in the research section below.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gary K Steinberg

$277,873.65

in general payments reported 2019-2025

Years
2019-2025
Top company
Surgical Theater. INC.
Context
The $8,823 reported for 2025 was more than what 85% of Neurological Surgery providers received nationally (typical 2025 total: $604).

https://glasscript.com/doctor/1217643/gary-k-steinberg

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.